【摘要】 目的 评价尤瑞克林联合丁苯酞在常规治疗基础上治疗进展性脑梗死的临床疗效。方法 将2018年1月至2022年12月安阳地区医院收治的100例进展性脑梗死患者随机分为两组，每组50例。两组均给予静脉溶栓、血管内介入治疗、抗血小板聚集、抗凝或降纤、扩容、调脂及神经保护等常规治疗。丁苯酞组在常规治疗的基础上使用丁苯酞氯化钠注射液。联合组在丁苯酞组治疗基础上联合注射用尤瑞克林进行治疗。两组均连续治疗2周。比较两组疗效、美国国立卫生研究院卒中量表(NIHSS)、Barthel指数评分、大脑前动脉(ACA)、大脑中动脉(MCA)、大脑后动脉(PCA)平均血流速度，以及血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、一氧化氮(NO)、超氧化物歧化酶(SOD)水平。结果 联合组治疗有效率高于丁苯酞组，差异有统计学意义(P<0.05)。治疗后，两组NIHSS评分较治疗前降低，且联合组低于丁苯酞组，两组Barthel指数评分较治疗前升高，且联合组高于丁苯酞组，差异有统计学意义(P<0.05)。治疗后，两组ACA、MCA、PCA平均血流速度均提升，且联合组高于丁苯酞组，差异有统计学意义(P<0.05)。治疗后，两组hs-CRP、IL-6、IL-8和TNF-α水平较治疗前降低，且联合组低于丁苯酞组，NO、SOD水平较治疗前升高，且联合组高于丁苯酞组，差异有统计学意义(P<0.05)。结论 在常规治疗的基础上使用注射用尤瑞克林联合丁苯酞氯化钠注射液治疗进展性脑梗死可取得较好疗效，减轻神经功能缺损程度，提高日常生活活动能力，改善脑部血流灌注，减轻炎症反应及氧化应激。更多还原

【Abstract】 Objective To evaluate the clinical efficacy of combining Urekin and Butenafine Hydrochloride in the treatment of progressive cerebral infarction based on conventional therapy. Methods From January 2018 to December 2022, 100 patients with progressive cerebral infarction admitted to Anyang District Hospital were randomly divided into two groups, with 50 cases each. Both groups received routine treatment including intravenous thrombolysis, endovascular interventional therapy, antiplatelet aggregation, anticoagulation or fibrinolysis, volume expansion, lipid regulation, and neuroprotection. The Butenafine group additionally received Butenafine Hydrochloride injection. The combined group received Urekin injection on top of the Butenafine treatment. Both groups continued treatment for 2 weeks. The study compared treatment efficacy, NIH Stroke Scale(NIHSS) scores, Barthel Index scores, mean blood flow velocities in the anterior cerebral artery(ACA), middle cerebral artery(MCA), and posterior cerebral artery(PCA), as well as serum levels of high-sensitivity C-reactive protein(hs-CRP), tumor necrosis factor-alpha(TNF-α), interleukin-6(IL-6), interleukin-8(IL-8), nitric oxide(NO), and superoxide dismutase(SOD). Results The combined group showed a higher treatment effective rate than the Butenafine group, with statistically significant difference(P < 0.05). After treatment, NIHSS scores decreased in both groups, with the combined group displaying a greater reduction than the Butenafine group; Barthel Index scores increased in both groups, with the combined group showing higher scores than the Butenafine group(P < 0.05). Post-treatment, the blood flow velocities in ACA, MCA, and PCA increased in both groups, with the combined group showing higher velocities than the Butenafine group(P < 0.05). Serum hs-CRP, IL-6, IL-8, and TNF-α levels decreased after treatment, with the combined group exhibiting lower levels than the Butenafine group; NO and SOD levels increased in both groups, with the combined group having higher levels than the Butenafine group(P < 0.05). Conclusion The combined use of Urekin injection and Butenafine Hydrochloride injection on a basis of conventional treatment can achieve favorable outcomes in treating progressive cerebral infarction, reducing the extent of neurological impairment, improving activities of daily living, enhancing cerebral hemodynamics, and alleviating inflammation and oxidative stress.更多还原